A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
Recruiting now · Phase 4 · Has a placebo group
Conditions studied: COVID-19
In brief
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
Key facts
- Study ID
- NCT06008860
- Run by
- University of Chicago
- People needed
- 280
- Starts
- 2023-07-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-11-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Chicago — Chicago, Illinois, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.